80 results about "Cns injury" patented technology

The invention discloses a multifunctional composite rehabilitation system for a patient suffering from central nerve injury. The multifunctional composite rehabilitation system comprises a database module, a data managing module, a man-machine interaction module, a function evaluating module, a prescription generating and managing module, a calculating module, a system control module and a safety protecting module. By utilizing the artificial intelligence, the human motion intension can be predicted and recognized, the man-machine coordination control is realized, and the active type rehabilitation treatment of the patient is finished; through a multisource signal collection, signal fusion and real-time control technologies, every function is organically combined, the coordinative rehabilitation treatment of every function module is realized, the rehabilitation effect is effectively improved and the labor consumption is reduced; during the process of rehabilitation, the patient is guided to finish the rehabilitation treatment step by step by using the virtual reality technology; through the interaction among a doctor, the patient and a computer, a progressive composite rehabilitation strategy according with the disease condition of the patient is comprehensively determined, so that the patient suffering fromnerve injury can receive the most effective rehabilitation treatment within a gold rehabilitation period of 50 days, and therefore, the maximization of the functional rehabilitation is promoted.

The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury.

Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.

The present application relates to methods, kits and compositions for improving a subject's recovery from CNS injury. In certain aspects, methods of the invention comprise administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.

The present invention provides compositions and methods for treating, preventing, or reversing neuronal dysfunction including cognitive decline, such as cognitive decline associated with aging and minimal cognitive impairment; severe neurodegenerative disorders, such as Alzheimer's disease; and neuronal dysfunction associated with loss of motor skills, such as Parkinson's disease and amyotrophic lateral sclerosis. The compositions and methods of the invention can also treat or prevent neuronal dysfunction resulting from CNS injury, such as stroke, spinal-cord injury, and peripheral-nerve injury. The compositions of the invention comprises a huperzine compound and a nicotinic compound.

The invention discloses a slave-type lower limb gait training rehabilitation robot system which is divided into a lower limb wearable exoskeleton robot and a slave robot. The slave-type lower limb gait training rehabilitation robot system comprises two translational degrees of freedom, two vertical weight loss degrees of freedom of the slave robot and six rotational degrees of freedom of two legs,hip and knee of the wearable robot. The lower limb wearable exoskeleton robot is fixed on lower limbs and waist of a patient and provides walking assistance according to the gait of the patient and helps the patient to complete the walking action; and the slave robot is connected with the lower limb wearable exoskeleton robot to play a role in supporting the patient and reducing the weight, so that the corresponding following movement can be realized according to the walking of the patient. The slave-type lower limb gait training rehabilitation robot system is mainly used for solving variouslower limb movement dysfunctions caused by the central nerve injury, provides the safe, long-acting and large-range gait training for the patient and can improve the lower limb rehabilitation trainingefficiency of the patient.

The invention belongs to the medicine technical filed, in particular to a preparation method of monomeric compound ginsenoside Rg1, ginsenoside Rb1 and total arasaponin and the application in the medicine field thereof. The fresh medicinal material, the dried medicinal material and the medicinal material on the market of Panax notoginseng are taken as the raw materials; according to the polarity and the solubility property of a compound, separation and purification are carried out by adopting the solvent extraction method, the crystallization process and the chromatography and total arasaponin powder is prepared by combining the common drying means, such as decompression concentration drying, freeze drying, vacuum drying and the like; by carrying out one or more methods of recrystal, normal phase, opposite phase silica gel column chromatography, daiamid column chromatography and sephadex chromatography and the like on the powder, the ginsenoside Rg1 and the ginsenoside Rb1 monomers are prepared. The medicines which take the ginsenoside Rg1 and the ginsenoside Rb1 monomers or the total arasaponin as the active ingredients can be used for preventing and/or curing the senile dementia, the neurodegenerative diseases, the cerebrovascular disorder, various dysmnesia, the central lesion and other diseases.

The invention belongs to the technical field of biological engineering, and relates to an NGF-Fc fusion protein and a preparation method thereof. The method comprises the following steps: constructing a human immune globulin IgG Fc and nerve growth factor (NGF) fusion gene expression vector through a genetic engineering means, transferring to a mammal cell to make the transferred mammal cell highly express and produce NGF-Fc fusion proteins, purifying, identifying and carrying out biological activity detection. The expression vector transferred mammal cell constructed in the invention can express bioactive NGF-Fc fusion proteins, so the expression level can be 150mg/L or above, and the obtained protein has good stability and long half life, and can be used to prepare drugs for treating Alzheimer's disease, diabetic peripheral neuropathy, Parkinson's disease, facial neuritis, craniocerebral trauma, trauma of spinal cord, acute cerebrovascular disease, encephalatrophy and other neurological diseases, and peripheral nerve injury acute cerebral vascular central nerve injuries induced by chemical drugs.

The invention belongs to the field of biological medicine, and particularly relates to a Nogo-A receptor binding peptide as well as a derivative and an application thereof. The amino acid residue sequence of the Nogo-A receptor binding peptide is HIYTALV or GFATITG. The derivative of the binding peptide is a product obtained through conventional modification of an amino terminal or a carboxyl terminal of a Nogo-A receptor binding peptide fragment on a Nogo-A receptor binding peptide amino acid side chain group or a product obtained by connecting a label used for peptide or protein detection or purification on the Nogo-A receptor binding peptide. The binding peptide and the derivative of the binding peptide can be bound with NgR in vitro, nerve regeneration is promoted by preventing binding of NgR and Nogo-A, nerve regeneration barriers caused by central nervous injury diseases can be treated, recovery of a central nervous function is promoted, and the binding peptide and the derivative can be widely applied in the medical and biological fields.

The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of : brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.

Proteins that are differentially expressed or elevated in tissue and biofluids after central nervous system injuries are described. Elevated or reduced levels of the proteins, alone or in various combinations or ratios, can be used to assess severity of central nervous system injury (CNS injury) including traumatic brain injury (TBI), traumatic spinal cord injury (SCI) and chronic traumatic encephalopathy (CTE). Time course measurements post CNS-injury of these proteins can be used to monitor progress or recovery over periods up to several months. Differentiation of acute, subacute and chronic injury can be diagnosed by comparing the protein levels in CNS-injury patients at days 1-3, day 4-10 with levels at day 30-180 in comparison with normal controls.

The invention relates to an aquagel material used to recover hurt nerve center. Wherein, it uses nerve center cross method to graft the layer adhesive protein (Laninin) with nerve grow activity to the molecule skeleton of transparent acid aquagel, to rpare the aquagel frame, which can accelerate the regeneration of nerve axon.

This invention relates to one functional central neutral damage dialogue test protein chip and its process method, which comprises the following steps: using protein chip to fix multiple central neutral system damage generation development key function abnormal protein factor antigen and its array; the said protein antigen and its array abnormal protein factors act as key property protein factors in the neutral system for inflammation and activation reaction and cell ion balance adjust and signal transmission.

A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3⁺ cells, CD19⁺ cells, CD56⁺ cells and optionally of CD16⁺ cells, for use in treatment of CNS injury is provided.

The invention relates to gene chip used for detecting functional central nervous damage diagnosis and the preparing method. said gene chip is equipped with oligonucleotide gene probe array, the oligonucleotide biomolecule of said probe array is the special biological gene factor playing improtant role in multiple central nervous system damage process simutaneously, relating to netural cell death and tissue necrosis, inflammation, irritated response, ion dysequilibrium inside cell, signal transmission, abnormal control of cell cycle, abnormal cell construction and nerve degeneration damage morbid physiology and molecular biology active gene, respectively. The gene chip can be used to check the conditioning way, expression level and change rule of biological factor relative to cerebral ischemia damage inside body in the beginning of clinic for high risk group of cerebral apoplexy, and to predict possibility of cerebral apoplexy; and used to conditioning way and change rule of special biological factor relative to nerve damage inside nerve cell after central nervous system damage, and relationship between cell death and disease occurancy, and provides checking criterion for cilinical treatment.

Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks.

The invention discloses an along-channel and collateral-conduction guiding feedback rehabilitation training system used for lower limb potential development training and belongs to the fields of lower limb movement dysfunction caused by central nervous injury and rehabilitation training equipment. The system is characterized in that the system is a computer man-machine conversion type system which combines a traditional Chinese medicine guiding technology with channel and collateral conduction to perform central nervous potential development and lower limb movement function reconstruction. An animation technology is used for simulating the program signal curve of lower limb movement, according to the 'target-power' mechanism, an elevation movement program or a signal sequence from weak to strong of a movement muscle signal curve is set, the potential development consciousness of a patient is trained through music and image matching six-step method traditional Chinese medicine guiding training, so that a physical exercise therapist calls a training module of the lower limbs through Vista software to train the patient for actual joint movement, and damping-exertion along-channel and collateral-conduction guiding feedback rehabilitation training is achieved. A computer is used for automatically calculating elevation differences between angle and bioelectric current waveforms of the knees of a normal person and the patient when the limbs are at different positions, so that the therapy effect is improved.

The invention provides a composition containing miR-124-3P and application thereof in a drug for inducing neuron formation, and belongs to the technical field of central nerve injury repairing. The composition comprises the miR-124-3P and an inducer, wherein the inducer is selected from one or several of a JAK (Janus Kinase) inhibitor, a p38-MAPK (Mitogen-activated Protein Kinase) inhibitor and anadenylate cyclase activator. The time for trans-differentiating reactive astrocyte into neurons by utilizing the composition provided by the invention is short, the steps are simple and convenient, induction components are less, and the composition is economic, effective and convenient.

The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury may include a traumatic brain injury or a spinal cord injury. The functional recovery may include autonomic functions, sensory functions, motor functions or the like.

The invention discloses a novel nanometer drug carrier loaded with methyllprednisolone. The novel nanometer drug carrier comprises methyllprednisolone and a carrier, wherein the carrier is an ibuprofen modified dextran nanometer microsphere, the particle diameter of the novel nanometer drug carrier loaded with methyllprednisolone is 120 to 160 nanometers, the preparation method of the novel nanometer drug carrier loaded with methyllprednisolone comprises two steps of synthesizing the ibuprofen modified dextran nanometer microsphere and preparing novel nanoparticles loaded with methyllprednisolone. The novel nanometer drug carrier loaded with methyllprednisolone disclosed by the invention has the advantages that the nanometer microsphere synthesized by ibuprofen modified dextran is taken as the carrier, so that methyllprednisolone can be effectively and targetedly delivered to injured parts, the half-life of methylprednisolone drugs can be effectively prolonged, and methyllprednisolone and ibuprofen can play a synergistic role on promotion of central nervous system injury repair.

A medicament for therapeutic and/or prophylactic treatment of pain such as neuropathic pain that occurs after peripheral or central nerve injury, which contains ginsenoside Rb1 as an active ingredient.